Lipoprotein(a): The Genetic Cardiovascular Risk Factor Most Australians Have Never Had Tested

Lipoprotein(a) — written as Lp(a) and pronounced "lipoprotein little a" — sits in an unusual position among cardiovascular biomarkers. It is one of the most heritable traits in human biology, one of the strongest independent risk factors for early coronary artery disease, and one of the most consistently overlooked tests in routine Australian pathology. Millions of people are walking around with significantly elevated Lp(a) and have never been told to check it.

Understanding why Lp(a) matters, who needs to test, and what the results actually mean in practice is increasingly essential for functional medicine practitioners, cardiologists working in prevention, and informed patients managing their own cardiovascular health.

What Is Lipoprotein(a)?

Lp(a) is a lipoprotein particle — structurally similar to LDL — with a distinctive additional protein attached called apolipoprotein(a), or apo(a). This apo(a) protein is encoded by the LPA gene on chromosome 6 and is covalently bonded to apolipoprotein B-100, the same protein that sits on the surface of LDL particles.

That structural similarity to LDL is part of what makes Lp(a) so clinically relevant. Like LDL, Lp(a) can deposit in arterial walls and contribute to plaque formation. But apo(a) has additional properties that LDL lacks: it interferes with fibrinolysis (the breakdown of blood clots) and promotes inflammation within the arterial wall. The result is a particle that contributes to atherosclerosis through multiple simultaneous mechanisms — lipid deposition, pro-inflammatory signalling, and impaired clot clearance.

Research also shows that Lp(a) preferentially accumulates in calcified plaques, which may explain the strong association between elevated Lp(a) and aortic stenosis — a connection replicated in large Mendelian randomisation studies.

Why Lp(a) Is Almost Entirely Genetic

Most cardiovascular risk factors respond substantially to lifestyle intervention. Blood pressure drops with sodium reduction and exercise. LDL cholesterol falls with dietary changes and statins. Triglycerides respond to carbohydrate reduction. Insulin sensitivity improves with weight loss.

Lp(a) is fundamentally different. Research consistently estimates that 70 to 90 percent of an individual's Lp(a) concentration is determined by genetic variation — primarily the number of "kringle IV type 2" repeats within the LPA gene. People with fewer repeats tend to produce higher concentrations of Lp(a). This is not a meaningfully modifiable trait. Diet, exercise, statins, and most other interventions have negligible effects on Lp(a) levels.

This genetic determination has two important implications. First, if you have elevated Lp(a), it is not because of anything you did wrong — it is inherited. Second, if you have elevated Lp(a), it is very likely that first-degree relatives share the same risk. A single positive test in a family should prompt cascade testing across siblings and children.

It also means that when practitioners encounter a patient with premature coronary artery disease, normal LDL, no metabolic syndrome, and no obvious lifestyle contributors, Lp(a) should be among the first investigations ordered. It is one of the few biomarkers where the result will not meaningfully change with repeat measurements over time, yet its predictive value for cardiovascular events is substantial and independent of other lipid fractions.

Why Standard Lipid Panels Miss Lp(a)

The standard fasting lipid panel — total cholesterol, LDL, HDL, and triglycerides — does not measure Lp(a). In some laboratories, Lp(a) cholesterol may be captured within the LDL calculation, which can slightly inflate the apparent LDL-C value. But the actual Lp(a) particle concentration is not reported, and there is no flag in a standard result set to alert a clinician that Lp(a) testing is absent.

For further context on the distinction between particle-based cardiovascular risk assessment and traditional cholesterol fractions, see the ApoB vs Lp(a) distinction at rawmarkers.com, which covers why ApoB measurement adds a different layer of risk information compared to Lp(a).

A person can have a "normal" LDL-C on a standard panel while carrying a very high Lp(a) burden. This creates a false sense of reassurance — especially in patients with a strong family history of early heart disease, where Lp(a) is a plausible explanatory factor that has never been investigated.

Understanding Lp(a) Reference Ranges

Lp(a) is measured in two ways: as mass concentration in mg/dL or as molar concentration in nmol/L. The nmol/L unit is increasingly preferred because it more accurately reflects particle number, avoiding some of the variability introduced by apo(a) isoform size differences. The two units are not directly interchangeable, and results must be interpreted in the context of which unit was used.

Standard Laboratory Reference Ranges

Most Australian laboratories report an upper reference limit of approximately 75 nmol/L or 30 mg/dL. Values below this level are generally considered within the normal population distribution.

Cardiovascular Risk Thresholds Used by Practitioners

The threshold for clinically significant Lp(a) risk is not the same as the population normal range. The European Atherosclerosis Society consensus position, widely referenced in prevention cardiology, identifies:

• Values above 125 nmol/L (approximately 50 mg/dL) as conferring high independent cardiovascular risk
• Values above 200 nmol/L as conferring very high risk, comparable in magnitude to familial hypercholesterolaemia

Approximately one in five people have Lp(a) above the 125 nmol/L threshold. In populations with a family history of premature coronary artery disease, the proportion is substantially higher.

Lp(a) risk is not entirely threshold-based. Risk appears to increase progressively across the distribution, meaning that someone at 100 nmol/L carries more risk than someone at 50 nmol/L, even if neither exceeds the 125 nmol/L clinical cutoff.

Risk Stacking With Other Biomarkers

The clinical impact of elevated Lp(a) is substantially amplified by the presence of other cardiovascular risk factors. Someone with elevated Lp(a) who also has systemic inflammation carries a compounded risk that is greater than either factor in isolation. A detailed discussion of inflammatory risk and CRP reference ranges is available in the CRP inflammation guide at rawmarkers.com, which provides useful context for practitioners managing cardiovascular prevention holistically.

Who Should Be Tested for Lp(a)?

Because testing is not universally available on Medicare and is not part of standard cardiovascular screening, practitioners need to prioritise testing in higher-yield groups. Current evidence supports testing in:

Family history of early cardiovascular disease: Any patient with a parent, sibling, or child who experienced a myocardial infarction, stroke, or coronary revascularisation before age 55 in men or 65 in women should have Lp(a) measured.

Established CVD with an unexplained cause: Patients who have had a cardiovascular event despite low or normal LDL-C, or without other conventional risk factors, warrant Lp(a) investigation.

Suspected or confirmed familial hypercholesterolaemia: Lp(a) is elevated at higher rates in this population, and coexistence significantly amplifies risk.

Intermediate cardiovascular risk on standard calculators: When standard risk calculators produce an intermediate result and the clinical picture is uncertain, Lp(a) testing can reclassify a meaningful proportion of patients into higher-risk categories.

Recurrent cardiovascular events despite well-managed conventional risk factors: For patients who continue to have events on optimal medical therapy, Lp(a) is a common undiagnosed contributor.

Aortic stenosis: Given the mechanistic and epidemiological link between elevated Lp(a) and aortic valve calcification, this population warrants testing.

Because Lp(a) is genetically determined and stable across adult life, a single lifetime measurement is generally considered sufficient in most individuals.

How to Test Lp(a) in Australia

Medicare and Private Pathology

Lp(a) testing is available in Australia through several pathways. It is not part of the standard Medicare-funded lipid panel and has historically required a specialist referral for Medicare rebate eligibility. GPs in Australia can order Lp(a) as an out-of-pocket private test through most major pathology providers including Sonic Healthcare, Australian Clinical Labs, and Sullivan Nicolaides.

Private Lp(a) testing typically costs between $20 and $60 depending on the laboratory and whether other markers are ordered concurrently. For the cost-to-information ratio, it is one of the more efficient cardiovascular risk investigations available in routine practice.

Practitioners should specify whether they want results in nmol/L or mg/dL. Requesting nmol/L improves consistency with international cardiovascular risk thresholds and is increasingly the preferred unit among prevention cardiologists.

Functional and Preventive Medicine Panels

Many Australian practitioners working in cardiovascular prevention now include Lp(a) as a standard component of comprehensive metabolic and cardiovascular panels, alongside ApoB, high-sensitivity CRP, HbA1c, fasting insulin, and homocysteine. This approach provides a considerably more complete picture of cardiovascular risk than the standard lipid panel alone.

The Current Evidence on Treatment

Because Lp(a) is genetically determined, the usual lifestyle levers that move other cardiovascular risk factors have limited efficacy. This makes the treatment conversation more nuanced than for most biomarkers.

Pharmacological Approaches

PCSK9 inhibitors: Evolocumab and alirocumab — injectable monoclonal antibodies approved in Australia for familial hypercholesterolaemia and high-risk CVD — reduce Lp(a) by approximately 20 to 30 percent in addition to their primary effect on LDL-C. For patients with both elevated LDL-C and elevated Lp(a), PCSK9 inhibitors offer a meaningful dual-target benefit. The cardiovascular outcome trials FOURIER and ODYSSEY OUTCOMES showed particularly strong risk reduction in participants with elevated Lp(a) at baseline.

Aspirin: Some evidence suggests aspirin may partially mitigate the thrombotic component of Lp(a)-related risk by counteracting the fibrinolysis-inhibiting properties of apo(a). This remains an area of active investigation, and the benefit-risk profile of aspirin varies substantially based on an individual's overall cardiovascular risk profile.

Niacin: Extended-release niacin reduces Lp(a) by 20 to 40 percent, but the AIM-HIGH and HPS2-THRIVE trials failed to demonstrate clinical benefit when niacin was added to statin therapy, and it carries a significant side-effect burden. It is rarely used in contemporary practice for this indication.

Emerging Therapies

Several Lp(a)-specific therapeutic approaches are in advanced clinical trials. Pelacarsen (an antisense oligonucleotide) and olpasiran (a small interfering RNA therapy) are both capable of reducing Lp(a) by 80 percent or more. The pivotal cardiovascular outcome trials for these agents are expected to report over the coming years, and if successful, they are likely to substantially change the management landscape for patients with markedly elevated Lp(a).

Omega-3 Fatty Acids

The Lp(a)-lowering potential of omega-3 fatty acids has been studied with modest and inconsistent results. High-dose EPA preparations have shown some signal in exploratory analyses, but the effect size is small and the literature is not sufficiently consistent to support omega-3 therapy as a dedicated Lp(a)-targeted intervention. A broader overview of the omega-3 EPA and DHA evidence base is available at consciousbitesnutrition.com for practitioners interested in the broader fatty acid research context.

What Practitioners Can Do Now

Given the current treatment landscape, management of elevated Lp(a) in clinical practice focuses on:

1. Aggressively managing all modifiable cardiovascular risk factors — LDL-C to low targets (often <1.8 mmol/L or lower in high-risk individuals), optimal blood pressure, smoking cessation, and glycaemic management.
2. Screening first-degree relatives.
3. Discussing PCSK9 inhibitor options where LDL-C also warrants treatment.
4. Using coronary calcium scoring for risk stratification in borderline cases.
5. Ensuring more frequent cardiovascular monitoring in high-risk individuals.

Key Takeaways for Practitioners and Patients

Lp(a) is a genetically determined, largely unmodifiable cardiovascular risk factor that operates through lipid deposition, pro-inflammatory signalling, and impaired fibrinolysis. It is absent from standard lipid panels, relatively inexpensive to test privately in Australia, and clinically significant in approximately one in five individuals.

Testing is most justified in patients with a family history of premature cardiovascular disease, established CVD without a clear conventional explanation, suspected familial hypercholesterolaemia, or intermediate cardiovascular risk on standard calculators. A single lifetime measurement is sufficient in most people.

Elevated results — particularly above 125 nmol/L — should prompt aggressive management of all co-existing modifiable cardiovascular risk factors, cascade family testing, and a candid conversation with the patient about the genetic nature of their risk and the evolving therapeutic landscape.

The field is moving quickly. Within the next few years, specific Lp(a)-lowering therapies may reach clinical availability in Australia. Knowing a patient's Lp(a) now positions both practitioner and patient to act when those options become accessible.

This article is for educational and informational purposes. It does not constitute medical advice. Consult a qualified healthcare practitioner before making any changes to testing, treatment, or management of cardiovascular risk.